BioWorld

March 6, 2007

Lilly Plans Hypnion Takeover, Getting Phase II Insomnia Drug

Less than two months after Phase II success with its insomnia drug, privately held Hypnion Inc. is being taken over by Eli Lilly and Co. for undisclosed terms. (BioWorld Today) Read More

Memory's MEM 1003 Misses In Bipolar Trial; AD Study Ongoing

VentiRx Raises $26.6M, Plans For Acquisition Of TLR Platform

Calistoga Secures $21M Series A Investment For p110 Delta Work

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 10, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors

BioWorld Science

Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.

Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors

BioWorld Science

Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...